REVLIMID® (lenalidomide) in combination with dexamethasone (dex) is indicated for the treatment of adult patients with multiple myeloma (MM). REVLIMID is indicated as maintenance therapy in adult patients with MM following autologous hematopoietic stem cell transplantation (auto-HSCT). REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.

FIRST Trial subanalysis.

In a post-hoc exploratory subanalysis, outcomes from the Rd Continuous FIRST Trial were evaluated based on depth of response.

FIRST, Frontline Investigation of REVLIMID + dexamethasone versus Standard Thalidomide; Rd, REVLIMID + dexamethasone.